Rivaroxaban (Xarelto)

Catalog No. A10800

Rivaroxaban is an oxazolidinone derivative optimized for inhibiting both free Factor Xa and Factor Xa bound in the prothrombinase complex.
  • Daniël Verhoef, .et al. Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors, Nat Commun, 2017, 8: 528 PMID: 28904343
  • Mizuki Yamamoto, .et al. Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay, Antimicrob Agents Chemother, 2016, Nov; 60(11): 6532-6539 PMID: 27550352
Catalog Num A10800
M. Wt 435.9
Formula C19H18ClN3O5S
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 366789-02-8
Synonyms BAY 59-7939, Xarelto
SMILES C1COCC(=O)N1C2=CC=C(C=C2)N3C[[email protected]@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl
Rivaroxaban is an oxazolidinone derivative optimized for inhibiting both free Factor Xa and Factor Xa bound in the prothrombinase complex.
Targets
Factor Xa (Cell-free assay) Prothrombinase (Cell-free assay)
0.7 nM2.1 nM
In vitro (25°C) DMSO 87 mg/mL (199.59 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose/0.2% Tween 80 5 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 22.94 mL 114.71 mL 229.41 mL
0.5 mM 4.59 mL 22.94 mL 45.88 mL
1 mM 2.29 mL 11.47 mL 22.94 mL
5 mM 0.46 mL 2.29 mL 4.59 mL

*The above data is based on the productmolecular weight 435.9. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.